BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 14997445)

  • 1. [Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues].
    Jouan-Flahault C; Casset-Semanaz F; Minini P
    Med Sci (Paris); 2004 Feb; 20(2):231-5. PubMed ID: 14997445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the limitations of statistical analysis of treatment outcomes used in periodontal research.
    Galgut PN
    J Int Acad Periodontol; 2003 Oct; 5(4):92-7. PubMed ID: 14604057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
    Sankoh AJ; D'Agostino RB; Huque MF
    Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity adjustment big and small in clinical studies.
    Hsu JC
    Clin Pharmacol Ther; 2010 Aug; 88(2):251-4. PubMed ID: 20592727
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues of simultaneous tests for noninferiority and superiority.
    Ng TH
    J Biopharm Stat; 2003 Nov; 13(4):629-39; discussion 641-62. PubMed ID: 14584713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALS issues in clinical trials. Statistical issues.
    Levin B
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():43-5. PubMed ID: 15512870
    [No Abstract]   [Full Text] [Related]  

  • 7. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p-value adjustments for subgroup analyses.
    Bristol DR
    J Biopharm Stat; 1997 May; 7(2):313-21; discussion 323-31. PubMed ID: 9136072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretations and conclusions in the clinical trial.
    Docherty JP
    J Clin Psychiatry; 2001; 62 Suppl 9():40-3; discussion 44-5. PubMed ID: 11379831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroups: time to go back to basic statistical principles?
    Keene ON; Garrett AD
    J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing and advancing the problem of missing data.
    Walton MK
    J Biopharm Stat; 2009 Nov; 19(6):945-56. PubMed ID: 20183457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and interpretation of data obtained from clinical trials in pain management.
    Theodore BR; Gatchel RJ
    Pain Pract; 2008; 8(6):461-72. PubMed ID: 19000174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical interpretation of statistical significance].
    López-Jiménez F
    Rev Invest Clin; 1996; 48(3):231-8. PubMed ID: 8966384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional multiplicity adjustment methods in clinical trials.
    Dmitrienko A; D'Agostino R
    Stat Med; 2013 Dec; 32(29):5172-218. PubMed ID: 24114861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to deal with multiple treatment or dose groups in randomized clinical trials?
    Hothorn LA
    Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What does "power of the study" mean? How to compute the power of a study? How to compute the number of subjects needed for a trial?].
    Mélot C
    Rev Mal Respir; 2003 Sep; 20(4):602-3. PubMed ID: 14528163
    [No Abstract]   [Full Text] [Related]  

  • 19. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
    Thorlund K; Devereaux PJ; Wetterslev J; Guyatt G; Ioannidis JP; Thabane L; Gluud LL; Als-Nielsen B; Gluud C
    Int J Epidemiol; 2009 Feb; 38(1):276-86. PubMed ID: 18824467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, operation, and interpretation of clinical trials.
    Pihlstrom BL; Barnett ML
    J Dent Res; 2010 Aug; 89(8):759-72. PubMed ID: 20581353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.